Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib in Chemosensitive Relapsed Aggressive Non-Hodgkin's Lymphoma
NCT00278382Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2005
- Primary completion
- Dec 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sorafenib in mantle cell lymphoma (MCL), primary mediastinal large B-cell lymphoma (PMBCL), diffuse large B-cell lymphoma (DLBCL) and 1 more, sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate up to 2 years. Started Oct 2005; status: completed.
02
Drugs
sorafenib
03
Conditions
mantle cell lymphoma (MCL)primary mediastinal large B-cell lymphoma (PMBCL)diffuse large B-cell lymphoma (DLBCL)anaplastic large cell lymphoma (ALCL)
Beyond the preview
Go deeper on NCT00278382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00278382.